Clinical Trial Search

Primary: Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6) — -11.8; -10.4 units on a scale — p=0.176

Primary: Proportion of Participants With an American College of Rheumatology (ACR) 20 Response at Week 14 — 24.9; 58.5 Percentage of Participants — p=<0.001

Primary: Proportion of Patients With Histologically Confirmed Recurrence Within One 1 Year. — 30.5; 47.3 precentage of participants — p=0.05

Primary: Proportion of Patients With >= 1 Ta or T1 Tumor Detected With Blue Light and Not White Light — 16.4 percentage of participants

Primary: Change in the 17 Item Hamilton Rating Scale for Depression (HAM-D-17) Score — -9.91; -7.41 units on a scale

Primary: Allogenic Blood Product Transfusion Risk — 47.4; 56.8; 52.5; 36.8 percentage of participants — p=0.72

Primary: Percentage of Patients That Experienced 1 or More Adverse Events — 59.0; 80.7 Percentage of patients

Primary: Time to Event Analysis: Number of Patients Experienced the First Confirmed Occurrence of Either Cardiovascular Death or Heart Failure (HF) Re-hospitalization Within 6…

Primary: ITP: Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS…

Primary: Admission Rate — 55; 76; 141; 107 participants

Primary: Part I: Seizure Frequency — 7.64; 6.73; 5.66; 5.35 ln (Seizures) per 4 weeks

Primary: Overall Survival Time — 21.22; 22.14 months — p=0.3802

Primary: Major Adverse Cardiac Events — 2 percentage of event

Primary: Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of the Study CDP870-033 (up to 84 Months) — 88.2 percentage of subjects

Primary: Number of Leaks Per Day — NA; NA Number of Leaks Per Day